Abstract
A key problem in Mental Health is that up to one third of patients suffering from major mental disorders develop resistance against drug therapy. However, patients showing early signs of treatment resistance (TR) do not receive adequate early intensive pharmacological treatment but instead they undergo a stepwise trial-and-error treatment approach. This situation originates from three major knowledge and translation gaps: i.) we lack effective methods to identify individuals at risk for TR early in the disease process, ii.) we lack effective, personalized treatment strategies grounded in insights into the biological basis of TR, and iii.) we lack efficient processes to translate scientific insights about TR into clinical practice, primary care and treatment guidelines. It is the central goal of PSYCH-STRATA to bridge these gaps and pave the way for a shift towards a treatment decision-making process tailored for the individual at risk for TR. To that end, we aim to establish evidence-based criteria to make decisions of early intense treatment in individuals at risk for TR across the major psychiatric disorders of schizophrenia, bipolar disorder and major depression. PSYCHSTRATA will i.) dissect the biological basis of TR and establish criteria to enable early detection of individuals at risk for TR based on the integrated analysis of an unprecedented collection of genetic, biological, digital mental health, and clinical data. ii.) Moreover, we will determine effective treatment strategies of individuals at risk for TR early in the treatment process, based on pan-European clinical trials in SCZ, BD and MDD. These efforts will enable the establishment of novel multimodal machine learning models to predict TR risk and treatment response. Lastly, iii.) we will enable the translation of these findings into clinical practice by prototyping the integration of personalized treatment decision support and patient-oriented decision-making mental health boards.
Project details
Unibo Team Leader: Chiara Fabbri
Unibo involved Department/s:
Dipartimento di Scienze Biomediche e Neuromotorie
Coordinator:
Westfalische Wilhelms-Universitat Munster(Germany)
Other Participants:
Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Maranon
(Spain)
Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung E.V.
(Germany)
ALMA MATER STUDIORUM - Università di Bologna
(Italy)
Universitair Medisch Centrum Utrecht (Umcu)
(Netherlands)
Katholieke Universiteit Leuven
(Belgium)
Icm Istitut Du Cerveau Et De La Moelle Epiniere
(France)
Fundacio Clinic Per A La Recerca Biomedica
(Spain)
Fundacio Centre De Regulacio Genomica
(Spain)
European Research Services GmbH
(Germany)
Universitetet I Oslo
(Norway)
Oslo Universitetssykehus Hf
(Norway)
Universita' Degli Studi Di Cagliari
(Italy)
Charite' Universitatsmedizin Berlin
(Germany)
Ludwig-Maximilians-Universitat Munchen (Lmu)
(Germany)
Kairos Gmbh
(Germany)
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Ev
(Germany)
Cardiff University
(United Kingdom)
Università degli Studi di BRESCIA
(Italy)
Global Alliance Of Mental Illness Advocacy Networks Europe Aisbl
(Belgium)
Region Hovedstaden
(Denmark)
Total Eu Contribution: Euro (EUR) 9.776.440,00
Project Duration in months: 60
Start Date:
01/10/2022
End Date:
30/09/2027